Can a Former FDA Chief Revive UnitedHealth’s Prospects?

UnitedHealth Group, the nation’s largest provider of Medicare plans, is navigating a severe operational storm. The company is contending with contracting profit margins, the loss of millions of insured members, and a depressed stock price. In a strategic move to address these challenges, the corporation has appointed Scott Gottlieb, the former head of the U.S. Food and Drug Administration (FDA), to its board of directors. The central question for investors is whether this high-profile appointment can catalyze a meaningful turnaround for the healthcare giant.

The scale of the difficulties facing UnitedHealth was laid bare in its third-quarter 2025 results, which revealed a dramatic compression in profitability. A year-over-year comparison shows Read more...